Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives

Simply Wall St.02-23

Amicus Therapeutics (FOLD) closed out FY 2025 with Q4 revenue of US$185.2 million and basic EPS of US$0.01, alongside net income excluding extra items of US$1.7 million, giving investors fresh data on...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613724712?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-02-23 07:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613724712","market":"sg","top_or_hot":-1,"title":"Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives","media":"Simply Wall St.","content":"<div>\n<p>Amicus Therapeutics (FOLD) closed out FY 2025 with Q4 revenue of US$185.2 million and basic EPS of US$0.01, alongside net income excluding extra items of US$1.7 million, giving investors fresh data on...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-23 07:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amicus Therapeutics (FOLD) closed out FY 2025 with Q4 revenue of US$185.2 million and basic EPS of US$0.01, alongside net income excluding extra items of US$1.7 million, giving investors fresh data on...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil","article_id":"2613724712","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613724712","pubTimestamp":1771802907,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Amicus Therapeutics (FOLD) closed out FY 2025 with Q4 revenue of US$185.2 million and basic EPS of US$0.01, alongside net income excluding extra items of US$1.7 million, giving investors fresh data on how the business is converting its top line into earnings. The company has seen quarterly revenue move from US$149.7 million in Q4 2024 to US$185.2 million in Q4 2025, while basic EPS shifted from US$0.05 to US$0.01 over the same period, creating a mixed picture on profitability trends. With...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BLSX":"Tradr 2X Long BLSH Daily ETF","BK4112":"金融交易所和数据","FOLD":"爱美医疗","BLSG":"2倍做多BLSH ETF-Leverage Shares","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4139":"生物科技","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"Amicus Therapeutics第四季度利润打印测试看涨的盈利能力叙述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FOLD":1.98,"BLSG":0.6,"BLSX":0.6},"content_text":"Amicus Therapeutics (FOLD) closed out FY 2025 with Q4 revenue of US$185.2 million and basic EPS of US$0.01, alongside net income excluding extra items of US$1.7 million, giving investors fresh data on how the business is converting its top line into earnings. The company has seen quarterly revenue move from US$149.7 million in Q4 2024 to US$185.2 million in Q4 2025, while basic EPS shifted from US$0.05 to US$0.01 over the same period, creating a mixed picture on profitability trends. With trailing 12 month figures still pointing to a loss, the latest print puts the focus on how margins evolve from here and whether recent improvements in net income can solidify. See our full analysis for Amicus Therapeutics. With the headline numbers on the table, the next step is to see how they line up against the widely followed growth and profitability narratives that have built up around Amicus over the past year. See what the community is saying about Amicus Therapeutics NasdaqGM:FOLD Earnings & Revenue History as at Feb 2026 AdvertisementTrailing 12 months still show a US$27.1 million loss  On a trailing 12 month basis to Q4 2025, Amicus booked US$634.2 million in revenue and a net loss excluding extra items of US$27.1 million, with basic EPS at a loss of US$0.09. Consensus narrative talks about a path toward GAAP profitability and high gross margins, yet the trailing figures still show losses. This means:\n     Even with quarterly net income turning positive at US$1.7 million in Q4 2025, the last 12 months as a whole did not translate into positive net profit margins. Improving loss trends over the last five years are referenced, but investors are still relying on forward expectations rather than a full year of profitable results in the recent data.    Revenue at US$634.2 million vs forecast 15.7% growth  Trailing 12 month revenue reached US$634.2 million, while forecasts cite revenue growth of about 15.7% per year, framing current sales against expectations for continued expansion. Bulls highlight faster growth than the broader US market and a rare disease opportunity set, but the current run rate raises a few checks for that view:\n     Forecasts reference earnings growth of roughly 41.8% per year and a move into profitability within three years, which is a different picture from the present US$27.1 million trailing loss. The bullish stance leans on long term revenue growth assumptions, so anyone using that story still has to bridge from US$634.2 million of revenue and a loss today to the higher earnings figures being discussed for future years.    Bulls argue that these results are the early stages of a much bigger earnings story, while others see a company that still has work to do before those forecasts are reflected in the bottom line. 🐂 Amicus Therapeutics Bull Case Unprofitable today with a 7.1x P/S and loss reduction trend  The company remains loss making over the last 12 months, but it is reported to have reduced losses at about 33.6% per year over five years and currently trades on a P/S of 7.1x, below peer and US Biotech averages. Bears focus on concentration in a few products and ongoing net losses, and the current numbers give them some points to work with:\n     Trailing net income excluding extra items of US$27.1 million in losses and the absence of positive net profit margins show that earnings dependence on Galafold and Pombiliti or Opfolda has not yet produced sustained profitability. At the same time, the P/S discount to peers and the presence of a Phase III product in the trailing 12 month data indicate that the market is already pricing in some of these risks rather than assigning a premium multiple.    Skeptics argue that until those losses fully reverse, product concentration and pricing or competitive pressures remain central to the story. 🐻 Amicus Therapeutics Bear Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Amicus Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. If the mixed messages here leave you unsure, that can be a useful starting point. Take a moment to review the full picture and weigh the optimism behind 4 key rewards. See What Else Is Out There Amicus is still reporting a trailing 12 month loss of US$27.1 million and remains unprofitable, with concentration in a small set of products. If you want ideas where the current numbers already point to quality and resilience rather than ongoing losses, our 87 resilient stocks with low risk scores can quickly surface alternatives worth your attention today.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613724712","isCrawlerRequest":true}